Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Greg Spendjian who wrote (3203)	1/24/2000 8:29:00 PM
From: Mark Bartlett	Respond to of 14101

Greg, << Is it incompetence at the HPB, understaffing at the HPB, or something fundamentally wrong with the application?>> The fact that the Feds told DMX they do NOT need any more info to make their decision, rules out the last, IMO. I suspect understaffed is the key one -- their budget is truly pathetic, considering the task they are charged with. Our elected officials should worry less about bailing out our NHL teams and more about getting meds approved. Lets hope it is not much longer. MB

To: Greg Spendjian who wrote (3203)	1/24/2000 8:46:00 PM
From: Montana Wildhack	Read Replies (1) \| Respond to of 14101

Greg, "...incompetence at the HPB, understaffing at the HPB, or something fundamentally wrong with the application?" I think its understaffing. Their budget has been trimmed over the years while their case load has increased. This has been commented on by Mark and others in the distant past. They have the benefit now of approval by a peer G7 country and the completion of the phase IV study. I should think we will see movement on it. The size of the phase IV and the strong results should help us greatly. I would think it will be a greater challenge to get a viable sales and distribution system going within Canada. At least we will probably have all of the customers (is patients the right word?) from that large study to begin with and the several hundred doctors who have already prescribed Pennsaid. The first step in Canada is obviously to contact them. The sales from this tiny group alone could exceed the Dioptic lab revenues. On another topic, I heard Rebecca say on the call that they were proceeding with pre-marketing preparations with JNJ. So that's the latest confirmation that things are progressing on that front. I would think we're all in agreement that that partnership will be successfully finalized. It's just good to hear reaffirmations that nothing has changed. So I think this change in volume and price (46,000 shares on the open at $4.95 and 152,000 in total on a day when everyone's attention must have been elsewhere in a major way) - could be an announcement on the way for: 1. Canadian approval of Pennsaid 2. Finalization of the JNJ distribution agreement 3. Press release concerning major WF10 developments Take your pick. They're all imminent.